HEALTHCARE & PHARMACEUTICALS MARKET RESEARCH
Tag: covid in children
-
ZyCoV-D : FIRST VACCINE FOR CHILDREN IN INDIA
Zydus Cadila’s DNA based vaccine ZyCoV-D becomes the first vaccine to receive emergency use authorization for children above 12 years of age. The three-dose vaccine has an efficacy rate of 66.6 per cent as per the trials conducted across the nation. Zydus’ needle free vaccine is only the second vaccine that is being produced in…
-
ZYDUS CADILA’S VACCINE TO BE JUST AS EFFECTIVE WITH A TWO- DOSE REGIMEN
Highlights: Fifth vaccine to be authorized in India. Now effective with two doses. Company to manufacture 120M doses a year. If approved, it could be World’s first plasmid DNA shot. Zydus Cadila, a leading Indian Pharmaceutical company is seeking approval from the DCGI for the EUA of its Covid-19 vaccine candidate, ZyCoV-D. It is the…
-
SII TO SUPPLY 20 CRORE COVAVAX DOSES BY DEC 2021
The Maryland based company, Novavax’s covid-19 vaccine candiate, named Covavax in India is all set to be launched in August-September this year in association with the Pune based Serum Institute of India. The vaccine has shown 90% efficacy in the clinical trials conducted in the U.S. With U.S. easing the availability of the key raw…
-
HOW LIKELY IS THE THIRD WAVE IN INDIA?
Several speculations are doing the rounds regarding the possibility of a third wave and if children are at a risk of getting infected in the subsequent wave. There is a lot of misinformation involved; however certain things need to be understood and implemented accurately so that we can look towards a foreseeable post pandemic future…
Follow Us
Recent Posts
-
Bedaquiline Role in Treating Tuberculosis having a hefty $1.38 billion dollar market
-
Adalimumab’s competition and immense market Growth Potential of 5.1%
-
Semaglutide’s massive influence on the Diabetes Pharmaceutical Market and 6 competitors
-
FDA approved Leqembi to have $12.9 billion sales
-
Assistive Technology Market; a $82B Growth Story
Tags
Autoimmunity cancer cancer research cancer therapy CDSCO covid-19 covid in children Diabetes drug Elderly Health FDA healthcare immune response Kerala mutations Nipah virus pandemic PCOS pharma Pharmaceutical market pharma sector protein-based vaccines sars-cov-2 therapy third wave Treatment vaccine variants WHO zydus cadila